Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria

Xiangling Wang¹, Gauri Bhutani¹, Lisa E. Vaughan², Felicity T. Enders², Zejfa Haskic¹, Dawn Milliner¹, John C. Lieske¹,³* and On behalf of the investigators of the Rare Kidney Stone Consortium

Abstract

Background: Patients with primary hyperoxaluria (PH) often develop kidney stones and chronic kidney disease. Noninvasive urine markers reflective of active kidney injury could be useful to gauge the effectiveness of ongoing treatments.

Methods: A panel of biomarkers that reflect different nephron sites and potential mechanisms of injury (clusterin, neutrophil gelatinase-associated lipocalin (NGAL), 8-isoprostane (8IP), monocyte-chemoattractant protein 1 (MCP-1), liver-type fatty acid binding protein (L-FABP), heart-type fatty acid binding protein (H-FABP), and osteopontin (OPN)) were measured in 114 urine specimens from 30 PH patients over multiple visits. Generalized estimating equations were used to assess associations between biomarkers and 24 h urine excretions, calculated proximal tubular oxalate concentration (PTOx), and eGFR.

Results: Mean (±SD) age at first visit was 19.5 ± 16.6 years with an estimated glomerular filtration rate (eGFR) of 68.4 ± 21.0 ml/min/1.73m². After adjustment for age, sex, and eGFR, a higher urine MCP-1 concentration and MCP-1/creatinine ratio was positively associated with CaOx supersaturation (SS). Higher urine NGAL and NGAL/creatinine as well as OPN and OPN/creatinine were associated with higher eGFR. 8IP was negatively associated with PTOx and urinary Ox, but positively associated with CaOx SS.

Conclusion: In PH patients greater urine MCP-1 and 8IP excretion might reflect ongoing collecting tubule crystallization, while greater NGAL and OPN excretion may reflect preservation of kidney mass and function. CaOx crystals, rather than oxalate ion may mediate oxidative stress in hyperoxaluric conditions. Further studies are warranted to determine whether urine MCP-1 excretion predicts long term outcome or is altered in response to treatment.

Keywords: Crystallization, Glomerular filtration rate, Monocyte-chemoattractant protein 1, Primary hyperoxaluria, Renal damage

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Primary hyperoxaluria (PH) is a group of autosomal recessive disorders characterized by recurrent urinary stones and nephrocalcinosis [1, 2]. Roughly half of PH patients present with advanced chronic kidney disease (CKD) at the time of diagnosis [1–3]. Three forms of PH have been recognized based on the underlying genetic defects. PH1 is caused by deficiency of hepatic peroxisomal alanine-glyoxylate aminotransferase (AGT) resulting from mutations in the AGXT gene, PH2 by deficiency of cytosolic and mitochondrial glyoxylate reductase/ hydroxypyruvate reductase, and PH3 by deficiency of mitochondrial 4-hydroxy-2-oxoglutarate aldolase [2].

The main biochemical defect in PH is overproduction of oxalate due to these enzyme deficiencies, primarily in the liver. The excess oxalate must then be excreted by the kidney [2]. In the kidney, oxalate can combine with calcium within renal tubules leading to nephrocalcinosis and kidney stones. Deposition of calcium oxalate within tubules and the interstitium and the immunological response can then produce progressive loss of renal function [4, 5]. Our recent study demonstrated that among PH patients higher urine oxalate excretion is an independent predictor of poorer renal outcome [6]. Thus, strategies to reduce urine oxalate excretion and/or calcium oxalate crystallization have been the cornerstone of PH treatment [2]. To date, improving fluid intake and use of neutral phosphate or potassium citrate as crystallization inhibitors have been the available options. Liver transplantation can replace the enzymatic defect in PH1 and perhaps also PH2, but carries inherent risk [7, 8]. Oral administration of oxalate degrading bacteria holds promise but remains an unproven strategy [9, 10]. Ribonucleic acid inhibition (RNAi)-based therapeutics that reduce hepatic oxalate production have been effective in animal models and are currently in clinical trials [4]. For any treatment plan, a sensitive marker of ongoing renal damage from oxalate and/or crystal would be a valuable tool to gauge the effectiveness of treatment in real time, and to assess whether oxalate excretion or crystallization has been sufficiently suppressed. Thus, in the current study we examined a panel of noninvasive candidate urine biomarkers of injury, which have been previously associated with inflammatory pathways, crystallization, and/or oxalate exposure in vitro or in vivo, in in order to determine if any correlated with urinary oxalate excretion, calcium oxalate supersaturation (CaOx SS), predicted proximal tubular oxalate concentration (PTOx), and estimated glomerular filtration rate (eGFR).

Methods
Study population
This study was approved by the institutional review board at the Mayo Clinic, Rochester Minnesota (IRB #2015–0053) and was performed in accordance with the declaration of Helsinki and all patients were consented to participate. Our study population consisted of a cohort of 30 PH patients enrolled in the Rare Kidney Stone Consortium (RKSC) PH registry between 2004 and 2013 who had one or more biobanked urine specimens and no prior history of end stage renal disease (ESRD) or organ transplantation; among these, n = 24 were PH type 1, n = 4 were PH type 2, and n = 2 were PH type 3.

General information and clinical manifestations were abstracted from Registry data. As described previously [6], PH1 was confirmed by mutations of the AGXT gene, liver biopsy confirming deficiency of AGT, or by marked hyperoxaluria in combination with hyperglycolic aciduria in a patient with no identifiable secondary causes. PH2 was established by mutations of glyoxylate and hydroxypyruvate reductase gene (GRHPR), liver biopsy confirming deficiency of GRHPR enzyme, or hyperoxaluria in combination with hyperglyceric aciduria without identifiable secondary cause. PH3 was diagnosed by mutations of the 4-hydroxy-2-oxoglutarate aldolase gene (HOGA1) [6].

Laboratory results including serum creatinine, 24-h urine oxalate (UOx), calcium, citrate, creatinine, and CaOx supersaturation (CaOx SS) calculated by the computer program EQUIL2 [11], were extracted from registry data. Proximal tubular oxalate concentration (PTOx = (UOx* serum Cr * 4)/ UCr) was calculated as described by Worcester and colleagues [12]. Laboratory values were retained for analysis if they were collected within 3 months of the clinic visit corresponding to the biobanked urine specimen; however the vast majority of observations were collected on the same day as the clinical visit. eGFR was calculated using the Schwartz formula in children < 18 years old [13] and the CKD-EPI formula in adults [14].

A cohort of n = 47 non-stone forming adults in good general health without kidney disease or diabetes (22 women, 25 men, ages ranging from 23 to 77 years) who completed 24-h urine collections on a free choice diet served as the adult control group to establish an adult reference range for the urine biomarkers we studied. These samples were obtained from subjects participating in a reference value study. Although a lack of a prior history of kidney disease or kidney stones was confirmed, no other laboratory or dietary data was available for this group.

Measurement of a panel of urine biomarkers
A 24 h urine sample was collected from patients at the time of an outpatient evaluation, centrifuged at 4 °C for 10 min at 2000 rpm, and the supernatant was frozen at -70 °C. For this study frozen aliquots were subjected to one prior freeze-thaw cycle. Urine monocyte
chemoattractant protein 1 (MCP-1) was measured using the Quantikine Human chemokine (C-C motif) ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP1) ELISA kit (R&D Systems, Minneapolis, MN) as previously described [15]. Urine liver-type fatty acid binding protein (L-FABP) was measured using the L-FABP urinary ELISA kit (Agrutus Medical, Daichi Fine Chemical Co., Ltd. Japan). Urine heart-type fatty acid binding protein (H-FABP) was measured using the H-FABP urinary ELISA kit (Hycult Biotech Inc., Plymouth Meeting, PA). Urine Neutrophil gelatinase-associated lipocalin (NGAL) was measured using the Bioporte immunoturbidometric assay run on a Roche COBAS autoanalyzer (Roche Diagnostics, Indianapolis, IN). Urine osteopontin (OPN) was measured using the OPN quantikine ELISA kit (R & D systems, Minneapolis, MN). Urine 8-isoprostane (8IP) was measured using the 8IP urinary ELISA kit (Cayman Chemicals, Ann Arbor, Michigan). Clusterin was measured using urinary clusterin ELISA kit (R & D, Minneapolis, MN). Urine creatinine was measured using the enzymatic creatinase assay on a COBAS auto analyzer (Roche Diagnostics, Indianapolis, IN). Duplicate measurements were performed for each ELISA measure, and those with a difference greater than 20% underwent repeat analysis. All urine biomarker concentrations were analyzed both with and without normalization to urine creatinine.

Statistical analysis
All data are presented as the mean ± SD (range) or median (25 percentile, 75 percentile) for normally and non-normally distributed continuous variables, respectively and n (%) for categorical variables. Urine biomarker measures as well as UOx, urine calcium/Cr, urine citrate/Cr, and PTOx were natural log transformed for analysis to account for the skewedness of the distributions. Given the wide age range of this cohort which encases both pediatrics and adults, urine oxalate was adjusted for body surface area (BSA) and calcium and citrate were normalized to urinary creatinine. Univariate logistic regression models were used to compare urine biomarker levels between PH patients and controls at their first visit. Odds ratios (OR) and 95% confidence intervals (95% CI) were reported from these models. The associations between the urine biomarkers and 24 h urine oxalate excretion (UOx), calculated CaOx SS, urine calcium/creatinine (CR), urine citrate/Cr, and calculated PTOx obtained from PH patients at one or multiple time points after diagnosis were evaluated using generalized linear estimating equations (GEE), which estimate robust standard error to take into account the correlated nature of the specimens within patients [16]. Parameter estimates from the GEE correspond to population averaged effects. GEE models were multivariate and in addition to each biomarker modeled separately, were also adjusted for the covariates age, sex and eGFR. The associations between the urine markers and eGFR were evaluated using multivariate GEE models adjusting for age and sex, PTOx, urine calcium/Cr, and urine citrate/Cr were only analyzed with biomarker concentrations, since urine creatinine had already been used to normalize these urine measures. P-values < 0.05 were considered statistically significant. All statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC).

Results
A total of 114 frozen bio banked urine specimens collected over multiple visits from 30 PH patients were available between 2004 and 2013. Among these 30 patients, 22 had more than one urine specimen available, ranging from 2 to 9 specimens per person over the course of 0.5 to 8.4 years. Patients in this cohort had a mean ± SD age of 19.5 ± 16.6 years and mean ± SD eGFR of 68.4 ± 21.0 ml/min/1.73m² at first visit, and consisted of 53% males (Table 1). Among these patients, n = 19 were < 18 at the time of their first visit, and 11 were > 18 years. The n = 47 adult controls that lacked a history of kidney disease or clinical stone events and were used for comparison to the adult PH patients ≥18 years old (n = 11) had a mean ± SD age of 48.2 ± 12.8 years and were 53.2% male. Compared to adult controls, adult PH patients had higher levels of NGAL and lower levels of Clusterin, MCP 1, OPN and H-FABP, both before and after adjustment for urinary creatinine concentration.

| Characteristic | PH Type 1 | PH Type 2 | PH Type 3 | Male | PH Type | 1 | 2 | 3 |
|---------------|-----------|-----------|-----------|------|---------|---|---|---|
| Age, years    | 19.5 ± 16.6 (3.4–68.2) |             |            | 16 (53.3%) |         | 24 (80.0%) | 4 (13.3%) | 2 (6.7%) |
| PH Type       |           |           |           |      |         |    |    |    |
| 1             |           |           |           |      |         |    |    |    |
| 2             |           |           |           |      |         |    |    |    |
| 3             |           |           |           |      |         |    |    |    |
| eGFR³, ml/min/1.73m² | 68.4 ± 21.0 (37.2–122.3) |             |            |      |         |    |    |    |
| Urine Oxalate, mMol/24 h/1.73m² | 1.48 (1.05, 2.33) |             |            |      |         |    |    |    |
| CaOx SS, DG²  | 0.99 ± 1.18 (--1.81–2.57) |             |            |      |         |    |    |    |
| PTOx, μmol/L  | 51.1 (34.1, 78.6) |             |            |      |         |    |    |    |
| Urine calcium/Cr ratio, mg/g | 5.98 (2.04, 8.68) |             |            |      |         |    |    |    |
| Urine citrate/Cr ratio, mg/g | 29.0 (17.7, 55.0) |             |            |      |         |    |    |    |

Data are presented as n (%) for categorical variables and mean ± SD (range) or median (25 percentile, 75 percentile) for continuous variables, depending on the skewedness of the distributions.

*a For patients >18, the CKD-EPI equation was used to estimate GFR. For patients <18, the Schwartz 2009 equation was used to estimate GFR.
*b DG: delta Gibbs, the units for CaOx SS.
Unadjusted 8 IP concentrations were slightly lower in PH patients compared to controls, ($P < 0.05$ for all). L-FABP concentrations were lower in the PH group compared to controls ($P = 0.004$), while no significant difference was found in creatinine-corrected L-FABP and 8 IP between cases and controls ($P = 0.66$) (Table 2).

Among the 30 PH patients, both unadjusted and creatinine-adjusted MCP 1 levels were positively associated with CaOx SS (Fig. 1a and b). As shown in Table 3, this association remained even after adjustment for age, sex, and eGFR. 8 IP concentration was also positively associated with CaOx SS, while negatively associated with PTOx. The creatinine-corrected biomarkers L-FABP and H-FABP were both positively associated with PTOx; L-FABP was also negatively associated with CaOx SS while H-FABP was positively associated with urinary oxalate. As shown in Table 4, after adjustment for age and sex, both urinary NGAL and OPN were positively associated with eGFR, with and without adjustment for urinary creatinine.

An additional sensitivity analysis was conducted after excluding those serum and/or urine clinical laboratory values that were obtained more than 1 week away from the biobanked urine used for the biomarker testing ($n = 7$ serum values and $n = 8$ urine values). The estimates and significance remained essentially unchanged (Supplementary Tables 1 and 2).

**Discussion**

In the current study, we used biobanked urine samples from a cohort of PH patients to determine the relationships between urinary biomarkers and renal function and urinary determinants of SS in this patient population. Urinary MCP-1 and 8 IP were both positively correlated with CaOx SS. Urinary excretions of other biomarkers including OPN and NGAL did not appear to associate with urinary excretions of oxalate or CaOx SS. Interestingly, however, urinary OPN and NGAL both positively associated with eGFR, suggesting their excretion might in part be related to intact renal mass.

MCP-1 is secreted following various stimuli by mononuclear cells and almost all types of intrinsic renal cells including mesangial cells, endothelial cells and tubular epithelial cells [17]. As an inflammatory chemokine, MCP-1 plays an important role in the development of kidney injury via recruitment and activation of monocytes/macrophages [17]. Studies have demonstrated that measurement of urinary MCP-1 has potential as a biomarker for diagnosis, prognosis and response to therapy in a variety of renal diseases including diabetic nephropathy, lupus nephritis, ANCA-associated vasculitis, and autosomal dominant polycystic kidney disease (ADPKD) [18–22]. Our recent study demonstrated that urine MCP-1 may even detect early tubulointerstitial fibrosis in living kidney donors with normal kidney function [22]. Earlier studies have demonstrated that exposure of cultured renal epithelial cells (NRK52E cells, a rat renal proximal tubular cell line) to calcium oxalate crystals resulted in increased expression of MCP-1 messenger RNA (mRNA) and protein [23]. Similar results were

| Biomarker | Cases, Median (IQR) | Controls, Median (IQR) | OR (95% CI) | P |
|-----------|---------------------|------------------------|-------------|---|
| Clusterin | 0.2 (0.1, 1.8)      | 8.6 (3.2, 16.1)        | 0.170 (0.048, 0.604) | 0.006 |
| Clusterin/Cr | 0.5 (0.2, 3.2)    | 7.7 (3.9, 16.3)        | 0.247 (0.106, 0.574) | 0.001 |
| NGAL | 16.0 (10.0, 23.0) | 2.0 (2.0, 4.0)         | 2.897 (1.322, 6.346) | 0.008 |
| NGAL/Cr | 34,483 (1818, 56,818) | 2817 (1747, 3718)      | 4.611 (1.890, 11.254) | < 0.001 |
| 8 IP | 589 (300, 793)      | 1172 (567, 1712)       | 0.188 (0.056, 0.637) | 0.007 |
| 8 IP/Cr | 1167 (1014, 1405)   | 1063 (695, 1302)       | 4.146 (0.615, 27.94) | 0.14 |
| MCP 1 | 38 (9, 81)          | 192 (96, 335)          | 0.159 (0.042, 0.596) | 0.006 |
| MCP 1/Cr | 87 (38, 147)        | 165 (130, 204)         | 0.268 (0.075, 0.957) | 0.043 |
| L-FABP | 2.0 (2.0, 2.0)      | 3.3 (2.9, 4.7)         | ~0 (~0, 0.003)       | 0.004 |
| L-FABP/Cr | 3.8 (2.9, 6.9)     | 3.6 (2.4, 4.8)         | 1.395 (0.358, 5.43)  | 0.63 |
| OPN | 43 (12, 141)        | 855 (386, 1618)        | 0.228 (0.093, 0.557) | 0.001 |
| OPN/Cr | 93 (44, 284)        | 847 (432, 1441)        | 0.323 (0.160, 0.649) | 0.002 |
| H-FABP | 293 (255, 1118)     | 2714 (1552, 4553)      | 0.149 (0.049, 0.450) | < 0.001 |
| H-FABP/Cr | 1063 (607, 2070)   | 2652 (1674, 3442)      | 0.201 (0.060, 0.666) | 0.009 |

P-values in bold denote significance at the 0.05 level. IQR is Intraquartile range. OR is odds ratio. 95% CI is for 95% confidence interval

Models were fit using logistic regression

Log transformations were taken for all urine biomarkers

Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL ng/ml and ng/g Cr, MCP1 pg/ml and pg/g Cr, L-FABP ng/ml and μg/g Cr, OPN ng/ml and μg/g Cr, H-FABP pg/ml and ng/g Cr
Table 3

| Biomarker | Uox | CaOx SS | PTOx | Calcium/ Cr | Citrate/ Cr |
|-----------|-----|---------|------|-------------|------------|
|           | Estimate (95% CI) | P | Estimate (95% CI) | P | Estimate (95% CI) | P | Estimate (95% CI) | P |
| MCP-1     | -0.195 (-0.898, 0.509) | 0.59 | 0.446 (0.207, 0.684) | <.001 | -0.135 (-0.769, 0.498) | 0.68 | -0.04 (-0.587, 0.507) | 0.89 | -0.14 (-0.494, 0.213) | 0.44 |
| MCP-1/Cr  | 0.083 (-0.538, 0.704) | 0.79 | 0.289 (0.084, 0.494) | 0.006 | 0.275 (-0.301, 0.851) | 0.35 | - | - | - | - |
| Clusterin | -0.43 (-0.981, 0.122) | 0.13 | 0.106 (-0.342, 0.555) | 0.64 | -0.503 (-1.031, 0.024) | 0.062 | -0.273 (-0.804, 0.258) | 0.32 | -0.139 (-0.566, 0.288) | 0.52 |
| Clusterin/Cr | -0.139 (-0.654, 0.377) | 0.60 | -0.168 (-0.56, 0.223) | 0.40 | -0.161 (-0.651, 0.328) | 0.52 | - | - | - | - |
| NGAL      | -0.025 (-0.612, 0.562) | 0.93 | 0.024 (-0.171, 0.219) | 0.81 | -0.139 (-0.673, 0.395) | 0.61 | -0.332 (-0.671, 0.007) | 0.055 | 0.16 (-0.124, 0.443) | 0.27 |
| NGAL/Cr   | 0.172 (-0.386, 0.729) | 0.55 | -0.154 (-0.35, 0.041) | 0.12 | 0.117 (-0.407, 0.641) | 0.66 | - | - | - | - |
| 8 IP      | -0.212 (-0.439, 0.014) | 0.067 | 0.208 (0.109, 0.308) | <.001 | -0.242 (-0.451, -0.033) | 0.023 | 0.082 (-0.087, 0.251) | 0.34 | -0.141 (-0.292, 0.01) | 0.068 |
| 8 IP/Cr   | 0.045 (-0.098, 0.188) | 0.54 | 0.043 (-0.021, 0.107) | 0.19 | 0.107 (-0.034, 0.249) | 0.14 | - | - | - | - |
| L-FABP    | 0.011 (-0.211, 0.234) | 0.92 | 0.053 (-0.026, 0.132) | 0.19 | 0.099 (-0.118, 0.316) | 0.37 | -0.038 (-0.163, 0.087) | 0.55 | -0.018 (-0.137, 0.1) | 0.76 |
| L-FABP/Cr | 0.279 (-0.001, 0.568) | 0.059 | -0.165 (-0.273, -0.058) | 0.003 | 0.421 (0.187, 0.654) | <.001 | - | - | - | - |
| OPN       | 0.253 (-0.383, 0.889) | 0.44 | 0.134 (-0.105, 0.373) | 0.27 | -0.019 (-0.629, 0.591) | 0.95 | 0.03 (-0.267, 0.327) | 0.84 | 0.22 (-0.319, 0.759) | 0.42 |
| OPN/Cr    | 0.514 (-0.113, 1.14) | 0.11 | -0.029 (-0.261, 0.202) | 0.81 | 0.345 (-0.275, 0.966) | 0.28 | - | - | - | - |
| H-FABP    | 0.062 (-0.23, 0.355) | 0.68 | 0.149 (-0.048, 0.346) | 0.14 | 0.006 (-0.305, 0.317) | 0.97 | -0.067 (-0.413, 0.279) | 0.70 | -0.116 (-0.335, 0.103) | 0.30 |
| H-FABP/Cr | 0.32 (0.033, 0.607) | 0.029 | -0.024 (-0.214, 0.166) | 0.81 | 0.353 (0.091, 0.615) | 0.008 | - | - | - | - |

*P*-values in bold denote significance at the 0.05 level

Models were fitted using the GEE procedure with the normal distribution, identity link and exchangeable correlation specifications, unless noted otherwise

Models were adjusted for age, sex and eGFR

Only the urine concentrations unadjusted for creatinine were used since these variables are also adjusted for creatinine

Log transformations were taken for all urine biomarkers as well as Uox, PTOx, Calcium/Cr and Citrate/Cr

Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL: ng/ml and ng/g Cr; 8 IP: pg/ml and ng/g Cr; MCP1: pg/ml and pg/g Cr; L-FABP: ng/ml and μg/g Cr; OPN: ng/ml and μg/g Cr; H-FABP: pg/ml and ng/g Cr
Values normalized and renal calcium oxalate crystal hyperoxaluric rats fed ethylene glycol [28], and these peroxides are increased in the kidneys and urine of activity [27]. Previous studies demonstrated that lipid superoxide and increased expression of NAPDH oxidase to oxalate and CaOx crystals, and is associated with increased MCP-1 gene and protein expression [31].

The urine of idiopathic calcium oxalate stone formers has increased amounts of N-acyl-β-glucosaminidase, α-glutathione S-transferase, malondialdehyde, and thio-barbituric acid reactive substances, suggesting a link between oxidative stress and stone disease in humans that parallels the observations in the hyperoxaluric rodent models [32]. Interestingly, in our study of PH patients, who are as a rule the most hyperoxaluric of CaOx stone formers, urinary 8 IP was negatively associated with PTOx and urinary oxalate excretion, but positively correlated with CaOx SS (Table 3). These findings might suggest that CaOx crystals (as opposed to oxalate ion) are the key stimulus for oxidative stress in these hyperoxaluric conditions. Indeed, since cell culture medium is high in calcium, exogenous addition of oxalate invariably leads to calcium oxalate crystallization, and studies to date have not effectively teased apart the effects of oxalate ion versus CaOx crystals.

Our data also suggest that higher levels of urine OPN and NGAL are associated with better kidney function. The underlying mechanism(s) may deserve further studies. OPN is a phosphorylated protein of wide tissue distribution that is found in association with dystrophic calcification including in the organic matrix of kidney stones. Although there is still debate regarding its effect upon crystal adhesion to tubular epithelial cells, studies have clearly demonstrated that OPN is a strong inhibitor of crystal formation and growth in vitro [33]. In the current study, urine levels of OPN were not independently associated with oxalate excretion, PTOx, or CaOx crystallization. Although the relatively small sample size could be a factor, it is also possible that urinary excretion of these biomarkers is also influenced by the amount of healthy renal mass, as reflected by eGFR. A similar rationale might be applied to urinary NGAL in the current study, which appears to have potential as a biomarker for acute kidney injury [34] and as a highly sensitive and specific predictor of systemic inflammatory response syndrome for patients presenting with nephrolithiasis [35]. In the case of OPN, it is also possible that CaOx crystallization could upregulate its production, but it is then incorporated into the developing crystals rather than excreted into the urine. Future prospective studies with larger group sizes may help further define the roles of osteopontin and NGAL in ongoing renal damage in PH.

| Table 4 Association of urine markers with eGFR among n = 30 PH patients |
|-----------------|-------|-------|
| Biomarker        | eGFR  |
| Clusterin       | 1.186 (0.42, 2.793) | 0.15 |
| Clusterin/Cr    | 1.377 (0.347, 3.102) | 0.12 |
| NGAL            | 2.598 (1.118, 4.077) | <0.001 |
| NGAL/Cr         | 2.207 (0.56, 3.855) | 0.009 |
| 8 IP            | 4.586 (0.05, 9.121) | 0.054 |
| 8 IP/Cr         | 2.509 (0.56, 3.855) | 0.31 |
| MCP-1           | 1.698 (0.569, 3.966) | 0.14 |
| MCP-1/Cr        | 1.507 (0.523, 3.536) | 0.15 |
| L-FABP          | −3.542 (−10.156, 3.072) | 0.29 |
| L-FABP/Cr       | −4.23 (−8.317, −0.143) | 0.043 |
| OPN             | 2.543 (0.751, 4.334) | 0.005 |
| OPN/Cr          | 2.223 (0.77, 3.676) | 0.003 |
| H-FABP          | 1.799 (−3.621, 7.218) | 0.52 |
| H-FABP/Cr       | 0.52 (−3.706, 4.746) | 0.81 |

P-values in bold denote significance at the 0.05 level.
Models were fit using the GEE procedure with the normal distribution, identity link and exchangeable correlation specifications, unless noted otherwise.
Models were adjusted for age and sex.
*Log transformations were taken for all urine biomarkers as well as Uox, PTOx, Calcium/Cr and Citrate/Cr.
Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL ng/ml and ng/g Cr, 8 IP pg/ml and ng/g Cr, MCP1 pg/ml and pg/g Cr, L-FABP ng/ml and μg/g Cr, OPN ng/ml and μg/g Cr, H-FABP pg/ml and ng/g Cr.

Reported in HK-2 cells, an immortalized proximal tubule epithelial cell line from normal adult human kidney [24]. In addition, exposure of renal fibroblasts to oxalate ion and CaOx crystals increased MCP-1 mRNA and protein expression [25]. In vivo studies in hyperoxaluric model by using oxalate-fed wild type mice (not genetically modified PH mice model) have also demonstrated increased MCP-1 expression with increasing CaOx crystal deposition [26]. The present study provides evidence that similar pathways are activated in hyperoxaluric PH patients, and that urinary MCP-1 excretion is associated with CaOx SS. It’s unclear why urinary MCP-1 (and clusterin and OPN and H-FABP) excretions were overall greater in the control population than the PH cohort (Table 2). This might reflect overall difference in kidney function or mass between the two groups related to disease status or possibly age or other comorbidities.

Urinary 8IP was also positively associated with urinary CaOx SS in the PH cohort. Studies suggest that this marker of oxidative stress is released by cells in response to oxalate and CaOx crystals, and is associated with superoxide and increased expression of NAPDH oxidase activity [27]. Previous studies demonstrated that lipid peroxides are increased in the kidneys and urine of hyperoxaluric rats fed ethylene glycol [28], and these values normalized and renal calcium oxalate crystal deposition improved with the co-administration of the antioxidant vitamin E [29]. Use of the NAPDH oxidase inhibitor apocyanin also reduced oxidative stress and crystal deposition in hyperoxaluric rat models [30]. The resulting oxidative stress and inflammation in these rodents is associated with increased MCP-1 gene and protein expression [31].
Our study has certain limitations. The number of patient samples was limited and they were not collected on a protocolized basis; thus results may have been biased towards those with more severe disease. However, this is one of the larger cohorts of patients with the rare disorder of PH to have a comprehensive panel of kidney injury biomarkers assessed. Furthermore, we lacked detailed clinical data from the control population including recent dietary intakes. However, the subjects lacked a clinical diagnosis of kidney disease or kidney stone disease and were a similar subset of the group used to define the reference ranges in our laboratory for kidney stone analytes. Thus, we have no reason to suspect that there urine composition would different any systematic way from the reference values in our laboratory.

Conclusions
Although the mechanisms are not entirely clear, CaOx crystallization in renal tubules has been considered as one of the critical therapeutic targets in the development of new therapeutic approach to treat PH. The association between urine level of MCP-1 and CaOx crystallization may suggest urine MCP-1 could be used as a marker to assist the evaluation for the effectiveness of treatments in PH patients. In addition, this association may suggest that MCP-1 signaling pathway might be involved in the etiology of renal damage in PH. Further prospective studies are warranted to determine whether urine excretion of MCP-1 can predict long term outcomes.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12882-020-01783-z.

Additional file 1: Supplemental Table 1. Association of urine markers with 24-hour urine oxalate excretion (Uox), CaOx supersaturation (CaOx SS), proximal tubular oxalate concentration (PTOx), urine calcium/Cr, and urine citrate/Cr, among n = 30 PH patients, after removing those with urine laboratory values obtained more than 1 week away from the corresponding urine biopsy specimen. P-values in bold denote significance at the 0.05 level. Models were fit using the GEE procedure with the normal distribution, identity link and exchangeable correlation specifications, unless noted otherwise. Models were adjusted for age and sex and eGFR. @ Only the urine concentrations unadjusted for creatinine were used since these variables are also adjusted for creatinine. Log transformations were taken for all urine biomarkers as well as Uox, PTOx, Calcium/Cr and Citrate/Cr. Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL: ng/ml and ng/g Cr; 8 IP: pg/ml and pg/g Cr; MCP1: pg/ml and pg/g Cr; L-FABP: ng/ml and μg/g Cr; OPN: ng/ml and μg/g Cr; H-FABP: pg/ml and ng/g Cr.

Additional file 2: Supplemental Table 2. Association of urine markers with eGFR among n = 30 PH patients, after removing those with serum creatinine values obtained more than 1 week away from the corresponding urine biopsy specimen. P-values in bold denote significance at the 0.05 level. Models were fit using the GEE procedure with the normal distribution, identity link and exchangeable correlation specifications, unless noted otherwise. Models were adjusted for age and sex. Log transformations were taken for all urine biomarkers as well as Uox, PTOx, Calcium/Cr and Citrate/Cr. Units of measure are Clusterin: ng/ml and μg/g Cr; NGAL: ng/ml and ng/g Cr; 8 IP: pg/ml and pg/g Cr; MCP1: pg/ml and pg/g Cr; L-FABP: ng/ml and μg/g Cr; OPN: ng/ml and μg/g Cr; H-FABP: pg/ml and ng/g Cr.

Abbreviations
AGT: Alanine-glyoxylate aminotransferase protein; AGXT: Alanine-glyoxylate aminotransferase gene; BSA: Body surface area; CaOx SS: Calcium oxalate supersaturation; CCL2: Chemokine (C-C motif) ligand 2; CI: Confidence interval; CKD: Chronic kidney disease; Cr: Creatinine; D.G.: Delta Gibbs free energy unit; eGFR: Estimated glomerular filtration rate; ESRD: End stage renal disease; GEE: Generalized estimating equation; GRHPR: Glyoxylate and hydroxypropanoate reductase; H-FABP: Liver-type fatty acid binding protein; HOGA1: 4-hydroxy-2-oxoglutarate aldolase; L-FABP: Liver-type fatty acid binding protein; 8IP: 8-isoprostane; MCP-1: Monocyte chemoattractant protein-1; mRNA: Messenger RNA; NGAL: Neutrophil gelatinase-associated lipocalin; OR: Odds ratio; OPN: Osteopontin; PH: Primary hyperoxaluria; PTOx: Calculated proximal tubular oxalate concentration; RKSC: Rare kidney stone consortium; RNAi: Ribonucleic acid inhibition; UOx: Urinary oxalate.

Acknowledgments
We thank the patients and their families for their gracious participation. We are grateful to the investigators of the RKSC coordinating sites and many additional individual contributors to the PH Registry for generously providing clinical data.

Investigators of the RKSC coordinating sites with contributions to the PH Registry include Dean Assimos (University of Alabama, Birmingham), Michelle Baum and Michael Somers (Children’s Hospital, Harvard Medical School), Lawrence Copelovitch (Children’s Hospital of Philadelphia), Prasad Devajaran (Cincinnati Children’s Hospital Medical Center), David Goldfarb (New York University), Elizabeth Harvey and Lisa Robinson (The Hospital for Sick Children [Sickkids], Toronto), William Haley (Mayo Clinic, Jacksonville), Mini Michael (University of Texas) and Craig Langman (Ann & Robert H. Lurie Children’s Memorial Hospital, Chicago).

Parts of this work were presented as an oral abstract at the 13th International Symposium on Urolithiasis, Tokyo, Japan in July 2016.

Authors’ contributions
XW analyzed data, and prepared manuscript draft. BG performed assay measurements, and critically reviewed manuscript. LEV performed statistical analysis of data, and critically reviewed manuscript. FTE performed statistical analysis of data and critically reviewed manuscript. ZH performed assay measurements. DM critically reviewed manuscript. JCL designed study, analysis of data, and critically reviewed manuscript. LEV performed statistical analysis of data and critically reviewed manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by the Rare Kidney Stone Consortium (US4DK083908), a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences’ (NCATS). This consortium is funded through collaboration between NCATS, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Oxalosis and Hyperoxaluria Foundation and the Mayo Foundation. OxThera, Inc. also provided partial funding for this study. The investigators had full responsibility for the study design, data collection, data interpretation, and preparation of the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the institutional review board #13–115351 at the Mayo Clinic, Rochester Minnesota. Written consent was obtained from study participants.

Consent for publication
Written consent was obtained from study participants to publish specific images or clinical details.
Competing interests
The authors declare no conflicts of interest or competing interests. This research is involving human subjects.

Author details
1. Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Received: 15 October 2019 Accepted: 23 March 2020
Published online: 15 April 2020

References
1. van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1: a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012;27(10):3885–62.
2. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649–58.
3. Cochat P, Hulton SA, Aquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1720–9.
4. Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56:103–22.
5. Knaf F, Asplin JR, Granja J, Schmidt IM, Moecck GW, David RJ, Flavell RA, Aronsen PS. NALP3-mediated inflammation is a principal cause of progressive renal failure in urinary oxophytrol nephropathy. Kidney Int. 2013;84(5):895–901.
6. Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS, et al. Predictors of incident ESRD among patients with primary Hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol. 2016;11(1):119–26.
7. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264–71.
8. Dhondup T, Lorenz EC, Milliner DS, Lieske JC. Combined liver-kidney transplantation for primary Hyperoxaluria type 2: a case report. Am J Transplant. 2018;18(1):253–7.
9. Miller AW, Dearing D. The metabolic and ecological interactions of oxalate-degrading bacteria in the mammalian gut. Pathogens. 2013;2(4):636–52.
10. Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017;5(2):29.
11. Werens PG, Brown CM, Smith LH, Finlayson B, EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol. 1985;134(6):1242–4.
12. Worcester EM, Evan AP, Coe FL, Lingeman JE, Krambeck AJ, Milliner DS, et al. Predictors of incident ESRD among patients with primary Hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol. 2016;11(1):119–26.
13. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264–71.
14. Dhondup T, Lorenz EC, Milliner DS, Lieske JC. Combined liver-kidney transplantation for primary Hyperoxaluria type 2: a case report. Am J Transplant. 2018;18(1):253–7.
15. Miller AW, Dearing D. The metabolic and ecological interactions of oxalate-degrading bacteria in the mammalian gut. Pathogens. 2013;2(4):636–52.
16. Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017;5(2):29.
17. Werens PG, Brown CM, Smith LH, Finlayson B, EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol. 1985;134(6):1242–4.
18. Worcester EM, Evan AP, Coe FL, Lingeman JE, Krambeck AJ, Milliner DS, et al. Predictors of incident ESRD among patients with primary Hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol. 2016;11(1):119–26.
19. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264–71.
20. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Roek M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis. 2010;56(5):883–95.
21. de Zeeuw D, Bekker P, Henkel E, Hassacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspan JH, Schall TJ, et al. The effect of CC2R inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 2015;3(9):887–96.
22. Wang X, Lieske JC, Alexander MP, Jayachandran M, Denic A, Mathew J, Lemman LO, Kremers WK, Larson JJ, Rule AD. Tubulointerstitial fibrosis of living donor kidneys associates with urinary monocye Chemoatractant protein 1. Am J Nephrol. 2016;43(4):545–9.
23. Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant. 2003;18(4):664–9.
24. Habitazadegah-Tari P, Byer KJ, Khan SR. Reactive oxygen species mediated calcium oxalate crystal-induced expression of MCP-1 in HK-2 cells. Urol Res. 2006;34(1):26–36.
25. Umekawa T, Iuchi M, Uemura H, Khan SR. Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int. 2006;98(3):656–60.
26. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA, Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol. 2002;168(3):1173–81.
27. Khan SR, Khan A, Byer KJ. Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol Dial Transplant. 2011;26(6):1778–85.
28. Thamilselvan S, Hackett RS, Khan SR. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol. 1997;157(3):1059–63.
29. Thamilselvan S, Menon M. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. BJU Int. 2005;96(1):117–26.
30. Khan SR, Glenton PA, Byer KJ. Modeling of hyperoxaluric calcium oxalate nephrolithiasis experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int. 2006;70(5):914–23. https://doi.org/10.1038/sj.ki.5001699.
31. Umekawa T, Chegini N, Khan SR. Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney Int. 2002;61(1):105–12.
32. Boorla C, Wunsuwun R, Tungsanga K, Tosukhowong P. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res. 2007;35(4):185–91.
33. Kleinman JG, Wesson JA, Hughes J. Osteopontin and calcium stone formation. Nephron Physiol. 2004;98(2):p43–7.
34. Kaiks N, Liakos C, Zouboulouglou F, Dagiadaki O, Dragasis S, Makris K. Neutophil Gelatinase-associated Lipocalin as an early marker of contrast-induced nephropathy after elective invasive cardiac procedures. Clin Cardiol. 2016;39(8):464–70.
35. Zhu W, Liu M, Wang GC, Che JP, Xu YF, Peng B, Zheng JH. Urinary Neutophil gelatinase-associated lipocalin, a biomarker for systemic inflammatory response syndrome in patients with nephrolithiasis. J Surg Res. 2014;187(1):237–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.